ABSTRACT
Background and Aims The HIV outbreak among People Who Inject Drugs (PWID) in Athens, Greece in 2011-2013 was the largest recent epidemic in Europe and North America. We aim to assess trends in HIV prevalence, drug use and access to prevention among PWID in Athens, to estimate HIV incidence and identify risk factors and to explore HIV-1 dispersal using molecular methods during 2014-2020.
Methods Two community-based HIV/hepatitis C programs on PWID were implemented in 2012-2013 (N=3,320) and 2018-2020 (N=1,635) through consecutive Respondent-Driven Sampling (RDS) rounds. PWID were uniquely identified across rounds/programs. We obtained RDS-weighted HIV prevalence estimates per round for 2018-2020 and compared them to 2012-2013. We assessed changes in HIV status, behaviours, and access to prevention in PWID participating in both periods. We estimated HIV incidence in a cohort of seronegative PWID as the number of HIV seroconversions/100 persons-years during 2014-2020 and used Cox regression to identify associated risk factors. Molecular sequencing and phylogenetic analysis were performed in HIV seroconverters.
Results HIV prevalence per round ranged between 12.0%-16.2% in 2012-2013 and 10.7%-11.3% in 2018-2020 with overlapping 95% Confidence Intervals (95% CI). Among PWID participating in both programs, HIV prevalence[95% CI] increased from 14.2%[11.7%-17.1%] in 2012-2013 to 22.0%[19.0%-25.3%] in 2018-2020 (p<0.001). There was a deterioration of socioeconomic characteristics such as homelessness (from 16.2%[95% CI: 13.5%-19.2%] to 25.6%[22.3%-29.0%]), a shift in cocaine use (16.6%[13.9%-19.6%] vs. 28.1%[24.7%-31.7%], reduced access to free syringes (51.8%[48.0%-55.7%] vs. 44.5%[40.7%-48.3%]) and a decrease in daily injecting (36.2%[32.6%-39.9%] vs. 28.5%[25.2%-32.1%]). HIV incidence (95% CI) in 2014-2020 was 1.94 (1.50-2.52) new cases/100 person-years and younger age, lower educational level, larger injection network and daily injecting were risk factors. Almost 9% of HIV seroconversions occurred within a newly expanding phylogenetic cluster.
Conclusions The ongoing HIV transmission among PWID in Athens provides empirical evidence that the current levels of prevention and treatment are inadequate to control the epidemic. Re-evaluation of prevention programs is urgently needed.
Competing Interest Statement
Conflict of interest statement
VS has received a grant by Gilead Sciences and Abbvie for the submitted work. She has served as a lecturer for Gilead, Abbvie, and Janssen.
DParaskevis has received grants from Gilead Sciences and GSK and participated in advisory boards of Gilead Sciences, GSK and MSD
MPsichogiou has received a grant by Gilead Sciences, served as a lecturer for Gilead, Abbvie and MSD and participated in advisory boards for Gilead, Abbvie and MSD
GK has received a grant by Gilead Sciences.
AH has participated in advisory boards for Gilead, AbbVie, BMS and received unrestricted grants: from AbbVie, BMS, Gilead, MSD, Novartis. He is Co-Chair of Hepatitis B & C Public Policy Association funded by AbbVie, Gilead, and MSD.
SR, EGK, EF, TA, SC, MPapadopoulou, IDP, MM, EH, MPylli, CT, DParaskeva, AB, have nothing to disclose.
Funding Statement
European Union and Greek national funds, Gilead Sciences, AbbVie, Hellenic Scientific Society for the Study of AIDS, STDs and Emerging Diseases, MSD, and Gilead Hellas.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The survey protocols and informed consent forms of the two programs were approved by the Institutional Review Boards of: i) the Medical School of the National and Kapodistrian University of Athens and ii) the Hellenic Scientific Society for the Study of AIDS, STDs and Emerging Diseases.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest statement VS has received a grant by Gilead Sciences and AbbVie for the submitted work. She has served as a lecturer for Gilead, AbbVie, and Janssen.
DParaskevis has received grants from Gilead Sciences and GSK and participated in advisory boards of Gilead Sciences, GSK, and MSD
MPsichogiou has received a grant by Gilead Sciences, served as a lecturer for Gilead, AbbVie and MSD and participated in advisory boards for Gilead, AbbVie, and MSD
GK has received a grant by Gilead Sciences.
AH has participated in advisory boards for Gilead, AbbVie, BMS and received unrestricted grants: from AbbVie, BMS, Gilead, MSD, Novartis. He is Co-Chair of Hepatitis B & C Public Policy Association funded by AbbVie, Gilead, and MSD.
SR, EGK, EF, TA, SC, MPapadopoulou, IDP, MM, EH, MPylli, CT, DParaskeva, AB, have nothing to disclose.
Data Availability
Data are not available for sharing.
